SCHEMBL1720050

SCHEMBL1720050

CCc1[nH]c(=O)c2cc(F)ccc2c1CN(C)C

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.38
PGR P06401 2/20 0.36
PARP3 Q9Y6F1 2/20 0.36
AR P10275 1/20 0.36
TNKS O95271 1/20 0.36
SLC6A4 P31645 1/20 0.35
MPO P05164 3/20 0.35
CNR1 P21554 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DAO P14920 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10227704 0.88 PARP1 (0.43) PARP1PGRPARP3ARMPO
SCHEMBL1719760 0.84 CYP3A4 (0.44) PARP1PGRPARP3ARTNKS
SCHEMBL1720082 0.83 PDE10A (0.46) PARP1TNKSMPOCNR1
SCHEMBL1719746 0.81 PARP1 (0.47) PARP1TNKSKDM4EALDH1A1HPGD
SCHEMBL13901573 0.81 PARP1 (0.40) PARP1PGRPARP3ARTNKS
Iodide SCHEMBL1719674 0.80 PARP1 (0.39) PARP1PGRPARP3ARTNKS
SCHEMBL1721096 0.76 PARP1 (0.43) PARP1TNKSMPOKDM4EALDH1A1
SCHEMBL1720554 0.75 MPO (0.45) PARP1PGRPARP3ARMPO
SCHEMBL1720655 0.72 MCL1 (0.41) PARP1TNKSSLC6A4ALDH1A1
SCHEMBL1720615 0.71 PARP1 (0.39) PARP1PGRPARP3ARKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885PGR 4800/4885PARP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.